Midazolam
- Generic Name
- Midazolam
- Brand Names
- Buccolam, Busulfex, Nayzilam, Seizalam
- Drug Type
- Small Molecule
- Chemical Formula
- C18H13ClFN3
- CAS Number
- 59467-70-8
- Unique Ingredient Identifier
- R60L0SM5BC
- Background
Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal...
- Indication
Midazolam has different indications depending on its formulation by the FDA.
Nasal
...
- Associated Conditions
- Epileptic seizure, Status Epilepticus
- Associated Therapies
- Anaesthesia, Anxiolytic therapy therapy, Sedation for mechanically-ventilated patients, Preoperative amnesia therapy, Preoperative sedation therapy
AZD1981 Midazolam CYP4503A Induction Study
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2009-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT00859352
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT00856362
Sedation and Pain (The Effect of IV Sedation on Pain Perception)
- Conditions
- Interventions
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 86
- Registration Number
- NCT00853333
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Bronchoscopy and Bispectral Index (BIS) - Guided Sedation
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 84
- Registration Number
- NCT00839371
- Locations
- 🇨🇭
Centre Valaisan de Pneumologie, Montana, Switzerland
Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2)
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2009-07-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00824057
- Locations
- 🇬🇧
Research Site, London, United Kingdom
The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2009-11-18
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 24
- Registration Number
- NCT00811837
- Locations
- 🇦🇹
Department of Anaesthesia, Medical University of Vienna, Vienna, Austria
To Relieve Pain and Anxiety - an Intervention Study in Ambulance Services
- Conditions
- Interventions
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2008-11-17
- Lead Sponsor
- Sahlgrenska University Hospital, Sweden
- Target Recruit Count
- 2800
- Registration Number
- NCT00792181
Determine the Effect of Multiple Doses of AZD7325, CYP Study
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2008-11-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00790114
The Effect of Remifentanil on Established Capsaicin-Induced Hyperalgesia in Human Volunteers
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2009-05-21
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 24
- Registration Number
- NCT00789386
- Locations
- 🇦🇹
Department of Anaesthesia, Medical University of Vienna, Vienna, Austria
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-06-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00783484
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.